Michal Segal

868 total citations
16 papers, 327 citations indexed

About

Michal Segal is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Michal Segal has authored 16 papers receiving a total of 327 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Oncology, 5 papers in Pulmonary and Respiratory Medicine and 4 papers in Cancer Research. Recurrent topics in Michal Segal's work include Colorectal Cancer Treatments and Studies (4 papers), Neuroendocrine Tumor Research Advances (3 papers) and Neuroblastoma Research and Treatments (3 papers). Michal Segal is often cited by papers focused on Colorectal Cancer Treatments and Studies (4 papers), Neuroendocrine Tumor Research Advances (3 papers) and Neuroblastoma Research and Treatments (3 papers). Michal Segal collaborates with scholars based in United States, Israel and Canada. Michal Segal's co-authors include Leslie R. Laufman, Ralph W. Roach, Marinela Capanu, Ellen Hollywood, Leonard B. Saltz, Laura H. Tang, David B. Solit, M. Catherine Pietanza, Diane Reidy‐Lagunes and Andrew D. Cohen and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Journal of Hepatology.

In The Last Decade

Michal Segal

16 papers receiving 314 citations

Peers

Countries citing papers authored by Michal Segal

Since Specialization

Citations

This map shows the geographic impact of Michal Segal's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michal Segal with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michal Segal more than expected).

Fields of papers citing papers by Michal Segal

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michal Segal. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michal Segal. The network helps show where Michal Segal may publish in the future.

Co-authorship network of co-authors of Michal Segal

This figure shows the co-authorship network connecting the top 25 collaborators of Michal Segal. A scholar is included among the top collaborators of Michal Segal based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michal Segal. Michal Segal is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

16 of 16 papers shown

#	Work	Indexed citations
1	Frequency of minimal residual disease as measured by ctDNA in mismatch repair deficient tumors following curative resection. 2021 ·Journal of Clinical Oncology ·Melissa Lumish, Gowtham Jayakumaran, (unknown), (unknown), Andrea Cercek, Zsofia K. Stadler, Geoffrey Y. Ku, Neil H. Segal, Elizabeth Won, Steven B. Maron, Tiffany A. Troso-Sandoval, Michal Segal, Vivian E. Strong, Daniela Molena, Martin R. Weiser, David R. Jones, Ahmet Zehir, Michael F. Berger, Luis A. Díaz, Yelena Y. Janjigian	2
2	CCL24 modulates fibrosis development in primary sclerosing cholangitis: correlation of human serum CCL24 levels with fibrosis markers and data from the Mdr2–/– mouse model. 2020 ·Journal of Hepatology ·Neta Barashi, Michal Segal, (unknown), (unknown), Adi Mor, Inbal Mishalian, Devorah Olam, Amnon Peled, Francesca Saffioti, Douglas Thorburn	1
3	First-line pembrolizumab (P), trastuzumab (T), capecitabine (C) and oxaliplatin (O) in HER2-positive metastatic esophagogastric adenocarcinoma (mEGA). 2019 ·Journal of Clinical Oncology ·Yelena Y. Janjigian, Joanne F. Chou, Marc Simmons, Parisa Momtaz, Francisco Sánchez-Vega, Marina Shcherba, Geoffrey Y. Ku, Elizabeth Won, Curtis R. Chong, Hans Gerdes, David P. Kelsen, David H. Ilson, (unknown), Michal Segal, Brittanie M Millang, Nikolaus Schultz, Pari Shah, David B. Solit, Marinela Capanu, Jaclyn F. Hechtman	44
4	Elevated Levels of Eotaxin-2 in Serum of Fibromyalgia Patients 2018 ·Pain Research and Management ·Victoria Furer, (unknown), Adi Mor, Michal Segal, (unknown), Valerie Aloush, Ori Elkayam, Jacob George, Jacob N. Ablin	15
5	Phase IB trial of cisplatin (C), gemcitabine (G), and veliparib (V) in patients with known or potential BRCA or PALB2-mutated pancreas adenocarcinoma (PC). 2014 ·Journal of Clinical Oncology ·Eileen M. O’Reilly, Maeve A. Lowery, Michal Segal, (unknown), Malcolm J. Moore, Hedy L. Kindler, Talia Golan, Amiel Segal, Erin Salo‐Mullen, Ellen Hollywood, Andrew S. Epstein, Marinela Capanu, Mary Ellen Moynahan, (unknown), Zsofia K. Stadler, Richard Kinh Gian, Alice P. Chen, Kenneth H. Yu, Laura H. Tang, David P. Kelsen	30
6	Randomized phase II study of gemcitabine (G), cisplatin (C) with or without veliparib (V) (arms A, B) and a phase II single-arm study of single-agent veliparib (arm C) in patients with BRCA or PALB2-mutated pancreas adenocarcinoma (PC). 2013 ·Journal of Clinical Oncology ·Eileen M. O’Reilly, Maeve A. Lowery, Kenneth H. Yu, Marinela Capanu, Zsofia K. Stadler, Andrew S. Epstein, Talia Golan, Amiel Segal, Michal Segal, Erin Salo‐Mullen, Laura H. Tang, Ellen Hollywood, Mary Ellen Moynahan, Richard Kinh Gian, Malcolm J. Moore, Hedy L. Kindler, Robert J. Mayer, Alice P. Chen, David P. Kelsen	7
7	A phase II clinical and translational study of MK-2206 in patients with metastatic neuroendocrine tumors (NETs). 2013 ·Journal of Clinical Oncology ·Diane Reidy‐Lagunes, M. Catherine Pietanza, Michal Segal, Marinela Capanu, Leonard B. Saltz	2
8	A phase 2 study of the insulin‐like growth factor‐1 receptor inhibitor MK‐0646 in patients with metastatic, well‐differentiated neuroendocrine tumors 2012 ·Cancer ·Diane Reidy‐Lagunes, Efsevia Vakiani, Michal Segal, Ellen Hollywood, Laura H. Tang, David B. Solit, M. Catherine Pietanza, Marinela Capanu, Leonard B. Saltz	56
9	A multicenter random assignment phase II study of irinotecan and flavopiridol versus irinotecan alone for patients with p53 wild-type gastric adenocarcinoma (NCI 8060). 2012 ·Journal of Clinical Oncology ·Yelena Y. Janjigian, Laura H. Tang, Stephen Shibata, David P. Kelsen, Michal Segal, (unknown), Gary K. Schwartz, L. Austin Doyle, Manish A. Shah	3
10	Phase I Study of Two Schedules of Oral S-1 in Combination with Fixed Doses of Oxaliplatin and Bevacizumab in Patients with Advanced Solid Tumors 2011 ·Oncology ·Ki Y. Chung, Kaku Saito, (unknown), Ellen Hollywood, Michal Segal, Leonard B. Saltz	4
11	A phase II clinical trial of MK-0646, an insulin-like growth factor-1 receptor inhibitor (IGF-1R), in patients with metastatic well-differentiated neuroendocrine tumors (NETs). 2010 ·Journal of Clinical Oncology ·(unknown), Ellen Hollywood, Michal Segal, Leonard B. Saltz	9
12	Monthly docetaxel and weekly gemcitabine in metastatic breast cancer: A phase II trial 2001 ·Annals of Oncology ·Leslie R. Laufman, C. Harris Spiridonidis, (unknown), Ralph W. Roach, Jeffrey Zangmeister, (unknown), Timothy M. Moore, Michal Segal, J. B. Jones, Tejal Patel, Lorence A. Gutterman, (unknown), (unknown), J. Philip Kuebler	46
13	[Testicular metastasis from transitional cell carcinoma of the bladder]. 1995 ·PubMed ·(unknown), (unknown), Michal Segal	2
14	Phase II study of pibenzimol in pancreatic cancer 1991 ·Investigational New Drugs ·Eric H. Kraut, T Fleming, Michal Segal, James A. Neidhart, Brent C. Behrens, J. S. Macdonald	32
15	Leucovorin plus 5-fluorouracil: an effective treatment for metastatic colon cancer. 1987 ·Journal of Clinical Oncology ·Leslie R. Laufman, (unknown), Ralph W. Roach, Michal Segal	56
16	The C-Test in Hebrew 1984 ·Language Testing ·Andrew D. Cohen, Michal Segal, (unknown)	18

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact